Wanbury Limited (BOM:524212)
India · Delayed Price · Currency is INR 180.65
-18.00 (-9.06%)
At close: Jan 21, 2026
Wanbury Revenue
Wanbury had revenue of 1.60B INR in the quarter ending September 30, 2025, a decrease of -0.70%. This brings the company's revenue in the last twelve months to 6.31B, up 9.34% year-over-year. In the fiscal year ending March 31, 2025, Wanbury had annual revenue of 6.00B with 3.88% growth.
Revenue (ttm)
6.31B
Revenue Growth
+9.34%
P/S Ratio
0.98
Revenue / Employee
4.57M
Employees
1,382
Market Cap
6.18B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 6.00B | 224.42M | 3.88% |
| Mar 31, 2024 | 5.78B | 780.91M | 15.63% |
| Mar 31, 2023 | 5.00B | -115.39M | -2.26% |
| Mar 31, 2022 | 5.11B | 1.19B | 30.23% |
| Mar 31, 2021 | 3.93B | 250.63M | 6.82% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Anuh Pharma | 7.30B |
| Venus Remedies | 6.99B |
| Lincoln Pharmaceuticals | 6.32B |
| Sudarshan Pharma Industries | 5.92B |
| Kopran | 5.92B |
| Fermenta Biotech | 5.63B |
| Fredun Pharmaceuticals | 5.31B |
| Bharat Parenterals | 3.57B |